Skip to main content
Premium Trial:

Request an Annual Quote

Alnylam Receives $10M from Takeda for Tech Transfer

Premium

Alnylam Pharmaceuticals said this week that it has received a $10 million payment from partner Takeda Pharmaceutical related to an alliance the companies formed in 2008.

According to Alnylam, the payment is specifically tied to the achievement of undisclosed objectives in the transfer of its platform technology, including documents, materials, and know-how to the Japanese firm for the development of RNAi-based therapeutics.

In mid-2008, Alnylam announced that it had signed a deal giving Takeda worldwide, non-exclusive access to its RNAi intellectual property and technology to help develop drugs for cancer and metabolic diseases (GSN 5/29/2008). In exchange, Alnylam received $150 million upfront, and was eligible to receive $50 million in technology-transfer payments, and up to $171 million in development and commercial milestones, as well as royalties.

The Scan

Guidelines for Ancient DNA Work

More than two dozen researchers have developed new ethical guidelines for conducting ancient DNA research, which they present in Nature.

And Cleared

A UK regulator has cleared former UK Prime Minister David Cameron in concerns he should have registered as a consultant-lobbyist for his work with Illumina, according to the Financial Times.

Suit Over Allegations

The Boston Globe reports that David Sabatini, who was placed on leave from MIT after allegations of sexual harassment, is suing his accuser, the Whitehead Institute, and the institute's director.

Nature Papers on Esophageal Cancer, Origin of Modern Horses, Exome Sequencing of UK Biobank Participants

In Nature this week: genetic and environmental influences of esophageal cancer, domestic horse origin traced to Western Eurasian steppes, and more.